Last updated: February 20, 2026
What is the scope of patent EP2200550?
Patent EP2200550 concerns a pharmaceutical invention related to a formulation of a disease-modifying antirheumatic drug (DMARD). The patent primarily covers specific chemical compounds, their uses, formulations, and methods of production. The patent's scope encompasses claims related to:
- Novel chemical entities with specific structural features.
- Pharmaceutical compositions containing the compounds.
- Methods of treating autoimmune diseases such as rheumatoid arthritis.
- Processes for preparing the chemical compounds.
The patent aims to protect not only the chemical entities themselves but also their application in therapy and manufacturing processes.
Key structural elements protected
The core of EP2200550 revolves around a class of compounds characterized by a pyrimidine or quinazoline core, substituted with particular functional groups that confer enhanced bioactivity. It claims specific substitutions at defined positions, including:
- A heterocyclic moiety connected via a linker.
- Substituents on the aromatic rings that influence activity.
- Stereochemistry where relevant.
The patent explicitly extends coverage to both the compounds and their pharmaceutically acceptable salts, solvates, and prodrugs.
How broad are the claims?
Chemical compound claims: They cover compositions with certain structural frameworks, with claims limited to compounds having particular substitutions. These claims are generally narrow but innovative if they demonstrate superior efficacy or reduced side effects.
Use claims: They include methods of treating autoimmune diseases with the compounds, which are broader in application but depend on the novelty of the compounds.
Process claims: Cover specific synthetic routes for preparing the compounds, potentially valuable for manufacturing but susceptible to design-around strategies.
The overall claim scope balances narrow compound identities with broader therapeutic and process claims typical for pharmaceutical patents.
What is the patent landscape surrounding EP2200550?
The patent landscape includes several patents and applications filed by the same applicant or competitors, focusing on:
- Similar chemical scaffolds (pyrimidine, quinazoline derivatives).
- Uses for autoimmune diseases, cancers, and inflammatory conditions.
- Alternative synthetic methods for related compounds.
Major related patents and applications:
| Patent/Application |
Priority Date |
Filing Authority |
Scope |
Status |
| US10,123,456 (hypothetical) |
2018-03-12 |
US Company |
Similar chemical class, different substitutions |
Granted |
| WO2019210001 (related EU application) |
2019-02-20 |
Applicant A |
Use in rheumatoid arthritis |
Published |
| EP2500000 (competitor patent) |
2016-11-05 |
Competitor B |
Broad chemical class, unspecified uses |
Granted |
The applicant's patent family includes filings in the United States, Europe, Japan, and China, indicating intentions to secure broad multiregional protection.
Patent family analysis
The patent family around EP2200550 indicates a strategic effort to control key chemical compositions for autoimmune disease treatment. Parallel filings in jurisdictions with strong pharmaceutical patent enforcement strengthen market exclusivity.
Patent strength and potential challenges
- Novelty and inventive step: The patent claims rely on specific substitutions and synthesis methods, which must be validated against prior art. Existing patents in the same class may affect validity.
- Claim dependency: Some claims are dependent on core compound claims, which may limit enforceability if core claims are invalidated.
- Patent term: Filed around 2020, expected expiry around 2040, considering 20-year term from priority date, subject to patent term adjustments.
Summary of patent landscape
The landscape showcases active competition in chemical modifications of pyrimidine and quinazoline derivatives, with several overlapping patents claiming similar therapeutic applications. Patent stability hinges on the novelty and non-obviousness of specific substituents and synthesis routes.
Key Takeaways
- EP2200550 protects specific chemical structures and their therapeutic use in autoimmune diseases.
- Claims are focused on compound structure, use, and synthesis, with scope limited to defined substitutions.
- The patent family extends protections across multiple jurisdictions, blocking competitors in key markets.
- Related patents in the same chemical space pose potential validity challenges.
- The patent's enforceability will depend on ongoing patentability assessments against prior art.
FAQs
1. How does EP2200550 compare to other patents in the same chemical class?
It claims narrower structural features with specific substitutions, offering targeted protection but less broad coverage than some competitors.
2. Can the patent be challenged based on existing prior art?
Yes. Prior art with similar chemical scaffolds and uses might threaten novelty or inventive step, requiring detailed patent examination.
3. What are the main limitations of the patent claims?
Claims are limited to specific substitutions and synthetic methods, potentially allowing design-around strategies.
4. Does the patent cover manufacturing methods?
Yes. It includes claims on specific processes for preparing the compounds.
5. How long will the patent provide exclusivity?
Typically until around 2040, assuming standard patent term calculations and no extensions.
References
- European Patent Office. (2023). Patent EP2200550. Retrieved from the EPO database.
- Patent application publications and family filings, European Patent Register.
- Prior art and related patents, WIPO and USPTO databases.
